Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02440685 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
A Phase 1 study, sponsored by Asana BioSciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02440685: Clinical Trial Phase 1 study, sponsored by Asana BioSciences.
NCT02440685 is a Phase 1 study that was terminated before completion, run by Asana BioSciences. The registered enrollment target is 51 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02440685, a Phase 1 study, was terminated before completion, sponsored by Asana BioSciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
Primary Outcome
Due to the early termination of the study, data for efficacy endpoints were insufficient for the planned efficacy analyses.
Interventions
- DRUG ASN002 Dose Escalation
- DRUG ASN002 RD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Why NCT02440685 stopped before completion
NCT02440685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 2 interventions - of which ASN002 Dose Escalation is the first listed.
NCT02440685 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02440685 about?
NCT02440685 is a clinical study titled "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors". This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
What is the current status of trial NCT02440685?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2015-05. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02440685?
The interventions under investigation include: ASN002 Dose Escalation (DRUG), ASN002 RD (DRUG).
Who is sponsoring clinical trial NCT02440685?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02440685's enrollment target sits among peer trials
51 969th of 2000 higher than 1,028 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia